Tracer library / [18F]fludarabine
[18F]fludarabine
Also written as [18F]Fludarabine; [F-18]Fludarabine
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- PET
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 1
What it is
- Compound class
- adenine nucleoside analog
- Target / mechanism
- —
- Clinical application
- PET imaging of hematological malignancies (lymphoma, leukemia, multiple myeloma) PMID 31058154
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| TRACERlab FX FN GE HealthCare | — | HPLC | 48 ± 3% decay-corrected | 99% | 2-nitro purine derivative 3 | 23836501 2014 Mol Imaging Biol based on a GE TRACERlab™ FX-FN module has been developed - The process afforded pure 2-[(18)F]fludarabine in 48 ± 3% yield (decay corrected to the EOB) in 85 min |
Need this precursor?We can point you to suppliers for [18F]fludarabine, or handle the enquiry for you.
Get in touchQuality control Preliminary - inferred from compound class
- Ph. Eur. monograph
- not verified No Ph. Eur. check is recorded for this entry.
- USP monograph
- not verified No USP check is recorded for this entry.
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [18F]fludarabine.
Get in touchNotes
Added from reverse module search (stage 6); 3 article(s) with F-18. Stage set/updated at stage 23 from PMID 31058154: 'All these favorable findings permitted to establish a "first in man" study where 10 patients were enrolled.'. | Stage 28: added indication(s) onc-leukemia from consolidated missing-rubric review. | Stage 30 (2026-09-18): Stage was 'first-in-human'; normalised to 'Clinical research', original wording kept here.